Does outcome/survival of patients with myelodysplastic syndromes should be predicted by reduced levels of adamts-13? results from a pilot study.

ConclusionsADAMTS-13 in MDS might represent a surrogate marker of prognosis, response to therapy, or disease progression. Further studies are needed.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research